$-0.67 EPS Expected for Stemline Therapeutics, Inc. (STML)

February 15, 2018 - By Kurt Siggers

 $ 0.67 EPS Expected for Stemline Therapeutics, Inc. (STML)
Investors sentiment increased to 1.24 in Q3 2017. Its up 0.24, from 1 in 2017Q2. It improved, as 6 investors sold Stemline Therapeutics, Inc. shares while 19 reduced holdings. 13 funds opened positions while 18 raised stakes. 12.54 million shares or 4.36% more from 12.02 million shares in 2017Q2 were reported.
Moreover, Edge Wealth Mgmt Ltd Com has 0% invested in Stemline Therapeutics, Inc. (NASDAQ:STML) for 500 shares. Bailard, a California-based fund reported 64,600 shares. State Street reported 349,585 shares or 0% of all its holdings. Gru One Trading Limited Partnership owns 1,309 shares. Tower Ltd Liability (Trc) invested in 0% or 2,909 shares. 2.00M were accumulated by Fmr Limited Liability Corp. State Of Wisconsin Board reported 16,000 shares. Carl Domino holds 0.35% or 26,000 shares in its portfolio. Barclays Public Ltd owns 18,410 shares. Farallon Mgmt Limited Liability Corp invested 0.12% of its portfolio in Stemline Therapeutics, Inc. (NASDAQ:STML). Citigroup holds 0% of its portfolio in Stemline Therapeutics, Inc. (NASDAQ:STML) for 70 shares. Bnp Paribas Arbitrage holds 2,317 shares. Rhumbline Advisers invested in 27,648 shares or 0% of the stock. Northern Tru Corp stated it has 286,147 shares. Pennsylvania-based Vanguard Grp Inc Incorporated has invested 0% in Stemline Therapeutics, Inc. (NASDAQ:STML).

Since December 15, 2017, it had 0 insider buys, and 3 selling transactions for $422,597 activity. $57,078 worth of stock was sold by Gionco David on Wednesday, January 17.

Analysts expect Stemline Therapeutics, Inc. (NASDAQ:STML) to report $-0.67 EPS on March, 15.They anticipate $0.11 EPS change or 19.64 % from last quarter’s $-0.56 EPS. After having $-0.68 EPS previously, Stemline Therapeutics, Inc.’s analysts see -1.47 % EPS growth. The stock increased 0.32% or $0.05 during the last trading session, reaching $15.9. About 130,888 shares traded. Stemline Therapeutics, Inc. (NASDAQ:STML) has risen 52.65% since February 15, 2017 and is uptrending. It has outperformed by 35.95% the S&P500.

Stemline Therapeutics, Inc. (NASDAQ:STML) Ratings Coverage

Among 4 analysts covering Stemline Therapeutics Inc (NASDAQ:STML), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Stemline Therapeutics Inc had 13 analyst reports since November 10, 2015 according to SRatingsIntel. H.C. Wainwright maintained it with “Buy” rating and $38.0 target in Thursday, December 14 report. The firm has “Outperform” rating given on Monday, February 6 by Wedbush. H.C. Wainwright maintained the shares of STML in report on Friday, February 2 with “Buy” rating. Cowen & Co maintained the shares of STML in report on Wednesday, June 14 with “Buy” rating. The rating was maintained by H.C. Wainwright with “Buy” on Monday, June 26. Jefferies maintained Stemline Therapeutics, Inc. (NASDAQ:STML) rating on Monday, June 26. Jefferies has “Buy” rating and $1600 target. The firm earned “Buy” rating on Friday, November 10 by H.C. Wainwright. The rating was maintained by Cowen & Co on Friday, June 23 with “Buy”. The stock of Stemline Therapeutics, Inc. (NASDAQ:STML) has “Buy” rating given on Wednesday, November 1 by H.C. Wainwright. The stock of Stemline Therapeutics, Inc. (NASDAQ:STML) has “Buy” rating given on Tuesday, September 12 by H.C. Wainwright.

Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercialization of proprietary oncology therapeutics in the United States. The company has market cap of $460.65 million. The firm develops SL-401, a targeted therapy directed to the interleukin-3 receptor , which is in Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm, myeloproliferative neoplasms, and acute myeloid leukemia; and in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma. It currently has negative earnings. It also develops SL-801, a novel oral small molecule reversible inhibitor of a tumor-promoting nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that is in Phase II clinical trial to attack brain cancer.

More important recent Stemline Therapeutics, Inc. (NASDAQ:STML) news were published by: Businesswire.com which released: “Newman Ferrara LLP Announces Corporate Governance Investigation of Stemline …” on January 08, 2018, also Fool.com published article titled: “Here’s Why Stemline Therapeutics Inc. Jumped 23% Higher in October”, Globenewswire.com published: “Stemline Therapeutics Closes $59.6 Million Public Offering of Common Stock” on January 26, 2018. More interesting news about Stemline Therapeutics, Inc. (NASDAQ:STML) was released by: Fool.com and their article: “The Clear Reason Why Stemline Therapeutics Inc. Skyrocketed as Much as 33%” with publication date: October 31, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.